Women are less likely than men to be given treatment for a potentially fatal heart condition, according to a new analysis.

ExoPTEN is being developed as a first-in-class, exosome-based therapy targeting high-impact neurological indications, including acute spinal cord injury, optic nerve damage, facial nerve injury, and ...

The revenue cycle management company partnered with UiPath to use AI to automate administrative tasks, like medical billing, ...

Loss of lifetime improved for patients with complications including stroke, HF and heart attack after a new atrial ...

The ACG has released new clinical guidelines for the management of ulcerative colitis and Crohn’s disease in adult ...

Core Solutions, Inc. (Core) is pleased to announce the appointment of licensed clinical psychologist Michael Arevalo, PsyD, as its new Director of Clinical Strategy. In this role, Dr. Arevalo leads ...

Under the partnership, GE HealthCare will serve as the technology partner, and TMC will be the clinical oncology partner.

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Pioneering small-molecule program, NT-0796, targets chronic ...

Neuromodulation has revolutionized the treatment of movement disorders such as Parkinson’s disease, dystonia, and essential tremor. With advancements in ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA ; Evrysdi offers the same efficacy and safety demo ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...